Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals focuses on developing therapies for rare chronic neuromuscular and neurological diseases. They offer Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS) patients. Ruzurgi treats pediatric LEMS patients. Firdapse also targets MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. The company has license agreements with BioMarin Pharmaceutical Inc. and Endo Ventures Limited. It was founded in 2002 and is based in Coral Gables, Florida.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital, an asset-light, cash-generative model and high, stable gross margins (pricing power).
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 21.8%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 21.8% against a cost of capital (WACC) of 7.7%, a spread of 14.1 percentage points.
- Pricing power: gross margin has held between 84% and 87% over the last 6 years (latest 85.2%).
- Our discounted cash flow model points to 33% upside (target price 41.88 USD), and even our pessimistic growth scenario implies 21%: a margin of safety.
- Asset-light, cash-generative model: capital expenditure takes only 4.3% of revenue and free cash flow was positive in each of the last 6 years.
Weaknesses
- Shareholder dilution: the share count has grown by 5.2% a year over the last three years.
- Deteriorating fundamentals over the last year: gross margin down 0.8 points and asset turnover down 7.6%.
Key Financial Data